Comparison between the effect of two regimens for hepatitis C treatment (Qurevo and Ribavirin) and (Sofosbuvir, Daclatsvir and Ribavirin ) on patients above and below the age of 60 years

Abstract

Abstract Background: The goal of antiviral treatment is to prevent complications of the disease, mainly cirrhosis and HCC. New therapy options, known as direct acting antiviral (DAA) regimens, offer the promise of increased success rates complimented by shorter treatment durations, improve side effect profiles, and simplified treatment monitoring. Aim of the work: To compare between the effect of oral antiviral treatment especially (Quervo and Ribavirin) and (Sofosbuvir, Daclatasvir and Ribavirin) between elderly patients above 60 years and young people below this age as regard: Response to treatment, Development of complication.